Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

Diego J. Maselli, Juan F. Fernandez, Christine Y. Whong, Kelly Echevarria, Anoop M. Nambiar, Antonio Anzueto, Marcos Restrepo

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gramnegative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.

Original languageEnglish (US)
Pages (from-to)43-51
Number of pages9
JournalInfection and Drug Resistance
Issue number1
StatePublished - May 28 2012


  • Ceftaroline
  • Cephalosporins
  • Community acquired pneumonia
  • Pneumonia
  • S. aureus
  • S. pneumoniae

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia'. Together they form a unique fingerprint.

Cite this